Home Business Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use

Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use

by news

Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.
source

Related Posts